Huber Financial Advisors LLC Lowers Stake in Celgene Co. (NASDAQ:CELG)

Huber Financial Advisors LLC cut its holdings in Celgene Co. (NASDAQ:CELG) by 78.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,000 shares of the biopharmaceutical company’s stock after selling 10,860 shares during the period. Huber Financial Advisors LLC’s holdings in Celgene were worth $283,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CELG. BlackRock Inc. lifted its holdings in shares of Celgene by 2.8% in the 4th quarter. BlackRock Inc. now owns 53,650,909 shares of the biopharmaceutical company’s stock worth $3,438,486,000 after acquiring an additional 1,459,100 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Celgene by 9,691.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 16,495,997 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 16,327,522 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Celgene by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 9,942,267 shares of the biopharmaceutical company’s stock valued at $636,179,000 after buying an additional 787,638 shares in the last quarter. Norges Bank bought a new stake in Celgene during the 4th quarter valued at about $484,390,000. Finally, Clearbridge Investments LLC lifted its holdings in Celgene by 9.2% during the 3rd quarter. Clearbridge Investments LLC now owns 7,133,588 shares of the biopharmaceutical company’s stock valued at $638,385,000 after buying an additional 598,631 shares in the last quarter. Institutional investors and hedge funds own 72.01% of the company’s stock.

Shares of CELG stock traded up $0.04 during trading hours on Friday, hitting $95.51. The company’s stock had a trading volume of 4,976,019 shares, compared to its average volume of 5,989,271. The company has a market capitalization of $67.36 billion, a P/E ratio of 12.55, a price-to-earnings-growth ratio of 0.44 and a beta of 1.68. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.78 and a quick ratio of 2.66. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $97.07.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.45 by $0.10. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The firm had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.01 billion. During the same period in the previous year, the business posted $2.05 EPS. The business’s revenue was up 13.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Celgene Co. will post 9.85 earnings per share for the current year.

A number of equities research analysts recently weighed in on CELG shares. Zacks Investment Research upgraded shares of Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 price objective for the company in a report on Wednesday, January 23rd. Cantor Fitzgerald restated a “buy” rating and issued a $100.00 price target on shares of Celgene in a report on Thursday, January 31st. Jefferies Financial Group lowered shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target for the company. in a report on Friday, February 1st. Cowen started coverage on shares of Celgene in a report on Tuesday, February 26th. They issued a “market perform” rating and a $102.00 price target for the company. Finally, William Blair reaffirmed a “buy” rating on shares of Celgene in a research report on Thursday, February 28th. Twenty investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $95.96.

In related news, Director Ernest Mario acquired 2,000 shares of Celgene stock in a transaction on Tuesday, February 12th. The stock was bought at an average cost of $89.99 per share, for a total transaction of $179,980.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.39% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/11/huber-financial-advisors-llc-has-283000-holdings-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: CBOE Russell 2000® Volatility Index

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.